Research & Development: Page 54
-
PharmaVoice Team/PharmaVoice
Why Outsourcing Patient Enrollment to a Specialist Makes Sense
Richard Malcolm, Ph.D., CEO, Acurian Disruptive change is needed in clinical trial management, an industry where inadequate enrollment has become the biggest driver of wasted dollars. The cost of patient enrollment is now the single largest part of the total trial budget, representing 32% of the ...
By Richard Malcolm • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: Help from The Outside
Help from the Outside Showcase Feature: Outsourcing Carolyn Gretton As life-sciences companies look to improve operational efficiencies within their organizations, they are increasingly reducing the number of activities that they would categorize as core competencies and outsourcing them to thir...
By Carolyn Gretton • Jan. 27, 2012 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Trends, Challenges, and Best Practices of Global Product Launches
Companies both large and small are expanding their global launch approach. Robin Robinson With all the variances and complexities involved in launching a product globally, especially around regulatory and approval requirements within various regions across countries, one could argue that there is...
By Robin Robinson • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
C-Suite CROs
Insights from the C-Suite: Contract Research Organizations CRO growth continues to outpace other sectors. Frost &?Sullivan estimates that the CRO market earned revenue of $11.43 billion in 2010 and estimates that the sector will top $20.09 billion in 2017. According to a recent Frost & Su...
By Taren Grom • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
Transformative Leadership
Taren Grom Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company, is leading her company to achieve an audacious goal: curing cancer. We are what we repeatedly do…excellence, then, is not so much an act, but a habit." This Aristotle quote is one of Deborah Dunsire, M.D...
By Taren Grom • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
Last Word
Creating Jobs in the Industry Safi Bahcall, Ph.D., CEO, Synta Pharmaceuticals, discusses how the extension of the R&D tax credit for life-sciences companies can accelerate job creation. PV: What do you think employment within the industry will look like in 2012? Bahcall: As the U.S. economy...
By Safi Bahcall • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
Talent Pool
executive appointments and promotions in the healthcare industry By Carolyn Gretton Pharmaceutical POOL Aaron BERG Essentialis Names CEO Essentialis, a pharmaceutical company focused on a novel medicine for the treatment of cardiovascular and metabolic disease, has promoted Aaron Berg to CEO, fro...
By Carolyn Gretton • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, marketing, And R&D?Trends affecting the healthcare industry By Carolyn Gretton Life-Sciences Companies Face Increased Complexity in Aggregate Spend Tracking and Reporting Trend: Aggregate spend mandates within the life-sciences industry are continuing to evolve in 2012 amid ongoing cha...
By Carolyn Gretton • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
What's New
New healthcare-related products, services, and companies By Carolyn Gretton New Alliance Promotes Trust in Online Physician Research Trend: Market research organizations, which base many critical decisions on insights from online physician panels, are taking collective action to ensure the integ...
By Carolyn Gretton • Jan. 26, 2012 -
PharmaVoice Team/PharmaVoice
UpFront
INDUSTRY at Large Milestones… Spectrum Celebrates 15 Years Spectrum, a health and science communications agency, is celebrating its 15th anniversary. The independent agency, which was founded by John Seng in 1996, is committed to achieving the goals of clients who are involved with issues, pro...
By Taren Grom • Jan. 26, 2012 -
PharmaVoice Team/PharmaVoice
Six Social Shifts: Trends Affecting Pharma Now
Like all things digital, the social media environment is moving so fast that even news from just three months ago seems old. The regulatory environment of pharma exacerbates the challenge to stay ahead of this social world. The pharma industry was anything but an early adopter in the social space...
By Whitney Poma • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
Global: R&D Outsourcing
Robin Robinson Outsourcing has always been about cutting costs and creating efficiencies, and today’s pressures have made the R&D process more global than ever. Myriad pressures have the industry looking toward global R&D outsourcing as a life raft in a sea of change. A U.K. report by Del...
By Robin Robinson • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
The Littlest Patients
Denise Myshko Incentives and mandates have spurred drugmakers to test many products in children and to enhance the pediatric information provided on drug labels. But experts say there is still a long way to go to address this specialty population. Over the past 15 years, biopharmaceutical co...
By Denise Myshko • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
Pharma 3.0 Next Steps
Robin Robinson Pharma Expands Disease Categories of 3.0 Efforts Between 2006 and 2009, 24% of Pharma 3.0 initiatives focused first on diabetes and metabolics. In 2010, oncology moved to the top with 15% of the year’s initiatives, and diabetes and metabolics tied for second with immunoscience/...
By PharmaVoice Team • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
What's New
New healthcare-related products, services, and companies By Carolyn Gretton Parexel Adds Commercialization to Repertoire Trend: A growing number of clinical development service providers are using their rich store of data and experience gleaned from clinical trial management to expand into commer...
By Carolyn Gretton • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, marketing, And R&D?Trends affecting the healthcare industry By Carolyn Gretton Pharma Turning to Health Outcomes Liaison Teams Trend: Trailblazing pharma companies are assembling elite health outcomes liaison (HOL) teams focused on market access priorities and supporting these groups ...
By Carolyn Gretton • Dec. 22, 2011 -
PharmaVoice Team/PharmaVoice
Online Investigator Training in Clinical Trials: A Roadmap For Success
A Roadmap for Success Successfully implementing online investigator training for clinical research sites requires technology and processes developed specifically for this purpose. As readers of this article are aware, research sites operate in a highly regulated and scrutinized environment. Sites...
By Suzanne Collins • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
The Increasing Role of the Patient in Phase IV Studies and Registries
Even though Phase IV studies and patient registries have been increasingly required by regulatory agencies for several years now and a wide range of technologies exist to design and manage them in an efficient manner, life-science organizations are still struggling to effectively implement large ...
By G. Chassaigne • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
Showcase Feature: Building a Better E-Machine
Carolyn Gretton Technological innovation remains essential to ensuring companies’ success in the data-driven Pharma 3.0 environment. According to Ernst & Young’s Progressions 2011 report, the next-generation pharma ecosystem continues to gain complexity, with initiatives expanding across a br...
By Carolyn Gretton • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
Global: A Shrinking World
Taren Grom Global reach, emerging markets, and cross-divisional expertise are playing an increasing role in all aspects of the life sciences, from R&D and clinical trials to sales and marketing. According to the IMS Institute for Healthcare Informatics, pharmerging markets will approach U....
By Taren Grom • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
R&D: The Drug Device Conundrum
Combining molecules with devices continues to be an evolving trend, but a lot of uncertainty exists around these combination products. There has been a movement toward convergence of technologies. More and more, drugs are being delivered or used in combination with a device with the intent to red...
By Denise Myshko • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
R&D: Global Regulatory Oversight
Growing regulatory requirements, continued standardization of submission and data requirements, and a continued focus on safety are just a few of the issues facing pharmaceutical companies. “With the FDA’s recent acceptance into PIC/S, an international agreement between countries’ regulatory ag...
By Denise Myshko • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
R&D: Strategic Outsourcing
CROs and pharmaceutical companies continue to finetune their strategic partnerships to gain a competitive edge. “”Companies are looking at outsourcing models that allow for sharper research focus, enhanced quality, improved efficiency, and offer a lower and more flexible cost base. " Alan Morgan...
By Denise Myshko • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
The C-Suite: Corporate Strategies
New Ways Forward Experts agree the time has come to re-evaluate the overall working culture of the life-sciences industry, and they say innovation, new payer models, new stakeholders, and new outcomes are key considerations for future success. “Pharma will need to generate data that are timely, r...
By PharmaVoice Team • Nov. 11, 2011 -
PharmaVoice Team/PharmaVoice
C-Suite: Executive Insights
CEOs, presidents, and executive management team members from across the industry — pharmaceutical, biotechnology, and service companies — discuss the most crucial factors driving change in the industry, as well as their strategies for meeting the challenges of business in the coming years. Jed Be...
By PharmaVoice Team • Nov. 11, 2011
Previous
